Combination of simvastatin and bone morphogenetic protein-2 enhances the differentiation of osteoblasts by regulating the expression of phospho-Smad1/5/8

  • Authors:
    • Jun-Beom Park
  • View Affiliations

  • Published online on: May 24, 2012     https://doi.org/10.3892/etm.2012.590
  • Pages: 303-306
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Statins inhibit 3-hydroxy-3-methylglutaryl-coen­zyme A reductase, which catalyzes the conversion of 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a rate-limiting step in cholesterol synthesis. A number of studies have demonstrated bone-promoting effects when simvastatin is applied locally with different carriers in various animal models. In the prsent study, the dose-dependent impact of simvastatin and bone morphogenetic protein-2 (BMP-2) on the cellular proliferation and differentiation of osteoprecursor cells was evaluated. The alkaline phosphatase activity (ALP) test was performed to assess differentiation, and protein expression related to bone formation, including that of phospho-Smad1/5/8 (pSmad1/5/8), was measured using western blot analysis to evaluate the underlying mechanism(s). Cultures grown in the presence of 0.1 µM simvastatin with 60 ng/ml BMP-2 exhibited the highest value for ALP activity. The results of the western blot analysis indicated that the addition of simvastatin upregulated pSmad1/5/8 expression and the combination of 0.1 µM simvastatin and 60 ng/­ml BMP-2 produced a significant increase in protein expression. Based on these findings, it was concluded that the combination of simvastatin and BMP-2 produced positive effects on the differentiation of osteoprecursor cells. The results also suggest that the combination of simvastatin and BMP-2 has synergistic effects that are achieved through the BMP pathway by enhancing the expression of pSmad1/5/8 expression.
View Figures
View References

Related Articles

Journal Cover

August 2012
Volume 4 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Park J: Combination of simvastatin and bone morphogenetic protein-2 enhances the differentiation of osteoblasts by regulating the expression of phospho-Smad1/5/8. Exp Ther Med 4: 303-306, 2012
APA
Park, J. (2012). Combination of simvastatin and bone morphogenetic protein-2 enhances the differentiation of osteoblasts by regulating the expression of phospho-Smad1/5/8. Experimental and Therapeutic Medicine, 4, 303-306. https://doi.org/10.3892/etm.2012.590
MLA
Park, J."Combination of simvastatin and bone morphogenetic protein-2 enhances the differentiation of osteoblasts by regulating the expression of phospho-Smad1/5/8". Experimental and Therapeutic Medicine 4.2 (2012): 303-306.
Chicago
Park, J."Combination of simvastatin and bone morphogenetic protein-2 enhances the differentiation of osteoblasts by regulating the expression of phospho-Smad1/5/8". Experimental and Therapeutic Medicine 4, no. 2 (2012): 303-306. https://doi.org/10.3892/etm.2012.590